Wei Li Lin
Director/Board Member chez HANDA PHARMACEUTICALS, INC.
Profil
Wei Li Lin is currently the Chairman of Chuan Fa Biotechnology Co. Ltd., Director-Supervisory Board of Microbio (Shanghai) Co., Ltd., and an Independent Director at Handa Pharmaceuticals, Inc. He previously served as Chairman, President & Spokesman at Fountain Biopharma, Inc. and as a Director at OBI Pharma, Inc. Dr. Lin holds a doctorate degree from Kansas State University.
Postes actifs de Wei Li Lin
| Sociétés | Poste | Début |
|---|---|---|
| HANDA PHARMACEUTICALS, INC. | Director/Board Member | 28/09/2017 |
| Microbio (Shanghai) Co., Ltd. | Director/Board Member | - |
| Chuan Fa Biotechnology Co. Ltd. | Chairman | - |
Anciens postes connus de Wei Li Lin
| Sociétés | Poste | Fin |
|---|---|---|
| OBI PHARMA, INC. | Director/Board Member | 20/12/2012 |
| FOUNTAIN BIOPHARMA INC | Chairman | - |
Formation de Wei Li Lin
| Kansas State University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OBI PHARMA, INC. | Health Technology |
| HANDA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Microbio (Shanghai) Co., Ltd. | |
Fountain Biopharma, Inc.
 Fountain Biopharma, Inc. Pharmaceuticals: OtherHealth Technology Fountain Biopharma, Inc. engages in the research, development and sales of antibody drugs. Its products include anti-allergic monoclonal antibody drugs, monoclonal antibody drugs, immune checkpoint aptamer drugs, anti-lag-3 immunological checkpoint aptamer drugs and anti-tumor stem cell labeled antibody drugs. The company was founded on November 25, 2010 and is headquartered in Taipei, Taiwan. | Health Technology |
| Chuan Fa Biotechnology Co. Ltd. |
